Clinical Trials
189 trialsKEYNOTE-B98
Merck Sharp & Dohme LLC
MK 7339-013
Merck Sharp & Dohme LLC
MK-4280A-007
Merck Sharp & Dohme LLC
MK-3475-06B
Merck Sharp & Dohme LLC
KANDLELIT-004
Merck Sharp & Dohme LLC
MK-3475-06C
Merck Sharp & Dohme LLC
MK-3475-01E
Merck Sharp & Dohme LLC
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
MK-3475-C66
Merck Sharp & Dohme LLC
TroFuse-007
Merck Sharp & Dohme LLC
MK-2870-010
Merck Sharp & Dohme LLC
TroFuse-011
Merck Sharp & Dohme LLC
TroFuse-033
Merck Sharp & Dohme LLC
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
TroFuse-036
Merck Sharp & Dohme LLC
MK-3475-01A
Merck Sharp & Dohme LLC
MK-3475-03A
Merck Sharp & Dohme LLC
MK-7339-012
Merck Sharp & Dohme LLC
MK-6482-022
Merck Sharp & Dohme LLC
INTerpath-009
Merck Sharp & Dohme LLC
LEAP-012
Merck Sharp & Dohme LLC
MK-3475-01C
Merck Sharp & Dohme LLC
KEYNOTE 975
Merck Sharp & Dohme LLC
MK-3475-689
Merck Sharp & Dohme LLC
KEYMAKER-U03
Merck Sharp & Dohme LLC
MK-6482-012
Merck Sharp & Dohme LLC
DE-01
AstraZeneca
KEYNOTE-C93
Merck Sharp & Dohme LLC
KEYLYNK-001
Merck Sharp & Dohme LLC
LEAP-005
Merck Sharp & Dohme LLC
MK-3475-676
Merck Sharp & Dohme LLC
KEYNOTE-991
Merck Sharp & Dohme LLC
KEYNOTE-937
Merck Sharp & Dohme LLC
TroFuse-008
Merck Sharp & Dohme LLC
KEYNOTE-966
Merck Sharp & Dohme LLC
INTerpath-012
Merck Sharp & Dohme LLC
KEYMAKER-U02
Merck Sharp & Dohme LLC
MK-1308A-008
Merck Sharp & Dohme LLC
MK-3475A-C18
Merck Sharp & Dohme LLC
KEYNOTE-966
Merck Sharp & Dohme LLC
MK-3475-775
Eisai Inc.
MK-4280A-010
Merck Sharp & Dohme LLC
PEARLS
Merck Sharp & Dohme LLC
MK-0472-001
Merck Sharp & Dohme LLC
KEYNOTE-B49
Merck Sharp & Dohme LLC
KEYNOTE-564
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
KEYNOTE-B96
Merck Sharp & Dohme LLC